LENZ Therapeutics Inc’s recently made public that its Chief Financial Officer Chevallard Daniel R. acquired Company’s shares for reported $49988.0 on May 14 ’24. In the deal valued at $15.68 per share,3,188 shares were bought. As a result of this transaction, Chevallard Daniel R. now holds 3,188 shares worth roughly $82537.32.
Then, MCCOLLUM JAMES W bought 31,332 shares, generating $501,093 in total proceeds. Upon buying the shares at $15.99, the Director now owns 525,565 shares.
A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Raymond James began covering LENZ with “an Outperform” recommendation on September 27, 2024. H.C. Wainwright started covering the stock on August 12, 2024. It rated LENZ as “a Buy”.
Price Performance Review of LENZ
On Tuesday, LENZ Therapeutics Inc [NASDAQ:LENZ] saw its stock fall -11.03% to $25.89. Over the last five days, the stock has lost -2.78%. LENZ Therapeutics Inc shares have fallen nearly -10.32% since the year began. Nevertheless, the stocks have risen 57.77% over the past one year. While a 52-week high of $38.93 was reached on 05/02/25, a 52-week low of $14.42 was recorded on 04/09/25. SMA at 50 days reached $24.36, while 200 days put it at $26.05.
Levels Of Support And Resistance For LENZ Stock
The 24-hour chart illustrates a support level at 24.92, which if violated will result in even more drops to 23.96. On the upside, there is a resistance level at 27.67. A further resistance level may holdings at 29.46. The Relative Strength Index (RSI) on the 14-day chart is 50.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.38, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 53.56%. Stochastics %K at 73.44% indicates the stock is a holding.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating .
